TDXd in HER2-Low Breast Cancer: A New Frontier in ADC Therapeutics
Key Takeaways
- HER2-low is a newly defined category
- ADC therapy effective in this group
- Expands treatment options significantly
- Testing for HER2-low status is important
Who is this video for?
Questions to ask your doctor
- What is my HER2 status?
- Am I eligible for this new therapy?
- What are the side effects?
Have questions about this topic?
Suchi can summarize key points and help you prepare questions for your doctor.
Ask Suchi about this video
